InMode Ltd.
INMD | NASDAQ
$14.50
+$0.15 (+1.05%)
At close: Sep 21, 2026, 4:00 PM ET
$14.55
+$0.05 (+0.34%)
Pre-market:
Sep 22, 2026, 9:21 AM ET
Company Profile
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Key Executives
| Name | Position |
|---|---|
| Moshe Mizrahy | Co-Founder, Chief Executive Officer & Director |
| Michael Kreindel | Co-Founder, Chief Technology Officer & Director |
| Moshik Itzkovich | Chief Financial Officer |
| Nava Tal-Launer | Chief Information Officer |
| Brandon Nye | Vice President of Sales of West US |
| Matt Rodgers | Vice President of Sales of Canada |
| Michael Dennison | President of North America |
| Yair Malca | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2026 | 6-K | Filing |
| Aug 05, 2026 | SC 13D/A | [Amend] Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 6-K | Filing |
| Aug 03, 2026 | 6-K | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 20, 2026 | 6-K | Filing |
| Jul 13, 2026 | 6-K | Filing |
InMode Ltd.
| Country | Israel |
| IPO Date | Aug 7, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 660 |
| CEO | Moshe Mizrahy |
Stock Details
| Ticker Symbol | INMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001742692 |
| CUSIP Number | M5425M103 |
| ISIN Number | IL0011595993 |
| SIC Code | 3845 |
Recent News
- 7 months ago / seekingalpha.comInMode Ltd. (INMD) Q4 2025 Earnings Call Transcript
- 7 months ago / prnewswire.comInMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million
- 8 months ago / prnewswire.comInMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
- 8 months ago / prnewswire.comInMode Responds to Transaction Rumors
Add to Watchlist
Select watchlists to add or remove INMD